×
About 9,875 results

ALLMedicine™ Hypertrophic Cardiomyopathy Center

Research & Reviews  3,470 results

Efficacy of Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy: A...
https://doi.org/10.1016/j.cpcardiol.2022.101524
Current Problems in Cardiology; Faraz F, Rehman MEU et. al.

Dec 2nd, 2022 - Atrial fibrillation (AF) is the most common arrhythmia in patients with hypertrophic cardiomyopathy (HCM). Catheter ablation (CA) has emerged as an effective therapy for AF. We conducted a meta-analysis to update the current clinical evidence on t...

Genome Editing and Pathological Cardiac Hypertrophy.
https://doi.org/10.1007/978-981-19-5642-3_6
Advances in Experimental Medicine and Biology; Kato T

Dec 2nd, 2022 - Three major genome editing tools, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), and clustered regularly interspaced short palindromic repeat (CRISPR) systems, are increasingly important technologies used i...

A Narrative Review of the Pathophysiology and Treatment of Hypertrophic Cardiomyopathy.
https://doi.org/10.14423/SMJ.0000000000001478
Southern Medical Journal; Gelpi Acevedo LM, Salinas AL et. al.

Dec 2nd, 2022 - Hypertrophic cardiomyopathy (HCM) is a genetic autosomal dominant disorder of the heart muscle that is characterized by left ventricular hypertrophy and sudden cardiac death. It is the most common inherited cardiac disease. HCM is defined by sarco...

Midterm results of latent outflow tract obstruction in hypertrophic cardiomyopathy afte...
https://doi.org/10.1111/jocs.17154
Journal of Cardiac Surgery; Han B, Wang S et. al.

Dec 1st, 2022 - The midterm clinical outcomes of patients with latent left ventricular outflow tract (LVOT) obstruction who undergo septal myectomy are unclear. Therefore, this study aimed to evaluate the clinical outcomes of patients with latent LVOT obstruction...

High-Resolution ECG for Predicting Ventricular Arrhythmia in Hypertrophic Cardiomyopath...
https://doi.org/10.1161/JAHA.122.028095
Journal of the American Heart Association; Gehi AK

Nov 30th, 2022 - High-Resolution ECG for Predicting Ventricular Arrhythmia in Hypertrophic Cardiomyopathy: Another Tool in the Toolbox.|2022|Gehi AK,|

see more →

Guidelines  10 results

Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic ...
https://doi.org/10.1016/j.echo.2022.03.012
Journal of the American Society of Echocardiography : Off... Nagueh SF, Phelan D et. al.

Jun 7th, 2022 - Hypertrophic cardiomyopathy (HCM) is defined by the presence of left ventricular hypertrophy in the absence of other potentially causative cardiac, systemic, syndromic, or metabolic diseases. Symptoms can be related to a range of pathophysiologic ...

2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic ca...
https://doi.org/10.1016/j.jtcvs.2021.04.001
The Journal of Thoracic and Cardiovascular Surgery; , Ommen SR et. al.

May 1st, 2021 - 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.|2021| ,Ommen SR,Mital S...

ACR Appropriateness Criteria® Nonischemic Myocardial Disease with Clinical Manifestatio...
https://doi.org/10.1016/j.jacr.2021.01.019
Journal of the American College of Radiology : JACR; , Rajiah P et. al.

Mar 3rd, 2021 - Nonischemic cardiomyopathies encompass a broad spectrum of myocardial disorders with mechanical or electrical dysfunction without evidence of ischemia. There are five broad variants of nonischemic cardiomyopathies; hypertrophic cardiomyopathy (Var...

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Ca...
https://doi.org/10.1016/j.jacc.2020.08.045
Journal of the American College of Cardiology; Ommen SR, Mital S et. al.

Nov 25th, 2020 - 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.|2020|Ommen SR,Mital S,B...

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Ca...
https://doi.org/10.1016/j.jacc.2020.08.044
Journal of the American College of Cardiology; Ommen SR, Mital S et. al.

Nov 25th, 2020 - This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting d...

see more →

Drugs  11 results see all →

Clinicaltrials.gov  181 results

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstru...
https://clinicaltrials.gov/ct2/show/NCT05489705

Oct 14th, 2022 - The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated in the real-world setting. The registry study also provide a real-world understanding of the curre...

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
https://clinicaltrials.gov/ct2/show/NCT04826185

Oct 13th, 2022 - The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM
https://clinicaltrials.gov/ct2/show/NCT05186818

Oct 13th, 2022 - The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

Renal Denervation in Hypertrophic Cardiomyopathy
https://clinicaltrials.gov/ct2/show/NCT05577208

Oct 13th, 2022 - According to current literature, approximately two-thirds of patients with HCM have persistent symptoms despite conventional treatment. For this reason, novel nonpharmacological therapies such as cardiac resynchronization, endocardial catheter abl...

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
https://clinicaltrials.gov/ct2/show/NCT04164732

Oct 10th, 2022 - The purpose of this study is to determine if LCZ696 is safe, tolerable and can improve exercise capacity (via improved peak VO2) in non-obstructive HCM patient population over the course of 50 weeks of treatment.

see more →

News  248 results

Promising Results in First Test of In Utero Enzyme-Replacement Therapy
https://www.medpagetoday.com/obgyn/pregnancy/101668

Nov 9th, 2022 - The first test of in utero enzyme replacement therapy (ERT) proved safe and effective for a baby with infantile-onset Pompe disease, according to a case report. An infant with cross-reactive immunologic material (CRIM)-negative infantile-onset Pom...

Myocardial Injury & COVID; Fewer Repeat Strokes; Video Games & Lethal Arrhythmias
https://www.medpagetoday.com/cardiology/prevention/101165

Oct 11th, 2022 - Myocardial injury, not pre-existing cardiovascular disease, was a significant predictor of in-hospital death and cardiovascular events in critically ill patients with COVID-19. (Circulation: Cardiovascular Quality and Outcomes) Recurrent ischemic ...

Myosin Inhibitor Aficamten Boosts QoL, Eases Symptoms in Obstructive HCM
https://www.medscape.com/viewarticle/982271

Oct 11th, 2022 - Patients with obstructive hypertrophic cardiomyopathy (HCM) who took the myosin inhibitor aficamten (Cytokinetics) showed major improvements in heart failure (HF) symptoms, functional capacity, hemodynamics, and quality of life in an observational...

Athletes With Mild HCM Can Likely Continue Competitive Sports
https://www.medscape.com/viewarticle/981782

Oct 3rd, 2022 - Athletes with mild hypertrophic cardiomyopathy (HCM) at low risk of sudden cardiac death (SCD) can safely continue to exercise at competitive levels, a retrospective study suggests. During a mean follow-up of 4.5 years, athletes who continued to e...

Ventricular Arrhythmia Clinical Practice Guidelines (ESC, 2022)
https://www.medscape.com/viewarticle/981520

Sep 30th, 2022 - Updated clinical guidelines for managing patients with ventricular arrhythmias and preventing sudden cardiac death were published in August 2022 by the European Society of Cardiology (ESC), in the European Heart Journal.[1] In patients presenting ...

see more →

Patient Education  30 results see all →